Stay updated on Nivolumab in Resected Esophageal Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Resected Esophageal Cancer Clinical Trial page.

Latest updates to the Nivolumab in Resected Esophageal Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing the previous v3.5.3. This indicates an updated version of the referenced document or page metadata.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page footer version label was updated from “Revision: v3.5.2” to “Revision: v3.5.3.” This reflects a site/version update and does not change the study details shown on the record.SummaryDifference0.0%

- Check38 days agoChange DetectedCollaborator name updated from Ono Pharmaceutical Co. Ltd to Ono Pharmaceutical Co., Ltd and the document revision advanced from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check66 days agoChange DetectedUpdated the revision label to v3.5.0 and removed the previous v3.4.3 entry.SummaryDifference0.0%

- Check81 days agoChange DetectedAdded the NEJM 2021 CheckMate 577 publication citation; removed the Erratum reference.SummaryDifference0.0%

- Check102 days agoChange DetectedA new revision label v3.4.2 was added to the study documents, replacing the previous v3.4.1.SummaryDifference0.0%

Stay in the know with updates to Nivolumab in Resected Esophageal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Resected Esophageal Cancer Clinical Trial page.